Physician profile
Dave Tien
NPI 1053319657
$2,083.21
in general payments reported to CMS, 2019-2025
26 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $39.55 · 2021: $163 · 2022: $309 · 2023: $452 · 2024: $379 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308 · Education: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.85 |
| Education | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $240.99 | 2019-2024 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $195.95 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.11 | 2021-2025 | Jardiance |
| Vifor Pharma, INC. | $186.07 | 2019-2024 | Veltassa |
| Amgen INC. | $143.04 | 2023-2025 | Tavneos |
| Travere Therapeutics, INC. | $117.50 | 2019-2024 | |
| Lilly USA, LLC | $95.78 | 2024-2025 | Jardiance |
| Renalytix Ai, INC. | $89.01 | 2022 | |
| Fresenius USA Marketing, INC. | $83.03 | 2022-2024 | Velphoro, Korsuva |
| Horizon Therapeutics Plc | $79.24 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $78.67 | 2021-2025 | Benlysta |
| Nxstage Medical, INC. | $69.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.05 | 2023-2025 | |
| Novo Nordisk INC | $53.28 | 2025 | Rybelsus, Ozempic |
| Calliditas Therapeutics US INC. | $53.10 | 2022-2025 | Tarpeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $46.55 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $46.16 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $42.95 | 2022-2024 | Livtencity |
| Ardelyx, INC. | $41.40 | 2024-2025 | Ibsrela |
| Chiesi USA, INC. | $35.52 | 2021 | |
| Alexion Pharmaceuticals, INC. | $26.84 | 2025 | Ultomiris |
| Veloxis Pharmaceuticals, INC. | $26.16 | 2025 | Envarsus |
| Cormedix INC. | $24.01 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $22.74 | 2025 | Empaveli |
| Genzyme Corporation | $18.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Tien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.